Great Point Partners LLC Decreases Stake in Autolus Therapeutics plc (NASDAQ:AUTL)

Great Point Partners LLC lessened its holdings in Autolus Therapeutics plc (NASDAQ:AUTL) by 18.3% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,811,955 shares of the company’s stock after selling 629,712 shares during the period. Autolus Therapeutics makes up approximately 3.0% of Great Point Partners LLC’s portfolio, making the stock its 15th biggest holding. Great Point Partners LLC’s holdings in Autolus Therapeutics were worth $10,207,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Price T Rowe Associates Inc. MD lifted its holdings in Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after acquiring an additional 2,487,778 shares during the period. Bayesian Capital Management LP purchased a new position in shares of Autolus Therapeutics in the 1st quarter worth about $100,000. B. Riley Wealth Advisors Inc. bought a new position in Autolus Therapeutics during the first quarter valued at about $108,000. Cetera Advisors LLC bought a new position in Autolus Therapeutics during the first quarter valued at about $839,000. Finally, SG Americas Securities LLC raised its position in Autolus Therapeutics by 853.2% in the second quarter. SG Americas Securities LLC now owns 189,240 shares of the company’s stock worth $659,000 after acquiring an additional 169,387 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AUTL. Needham & Company LLC reissued a “buy” rating and set a $9.00 target price on shares of Autolus Therapeutics in a research report on Monday, November 11th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $10.15.

Autolus Therapeutics Trading Up 4.0 %

Autolus Therapeutics stock opened at $3.10 on Wednesday. The firm has a market capitalization of $824.88 million, a price-to-earnings ratio of -2.46 and a beta of 2.04. The firm has a 50 day simple moving average of $3.77 and a 200 day simple moving average of $3.93. Autolus Therapeutics plc has a 1-year low of $2.69 and a 1-year high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same quarter in the prior year, the company posted ($0.26) earnings per share. On average, equities research analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.